AIM: Preoperative chemotherapy followed by radical surgery is an attractive treatment for locally advanced colon cancer (LACC) given the promising results of this approach in other locally advanced tumours. The study evaluates the outcome and treatment-related complications of perioperative oxaliplatin- and capecitabine-based chemotherapy and surgery for clinical Stage III colon cancer. METHOD: Twenty-two consecutive patients with a CT-staged LACC were included. All were staged at baseline and before surgery. Surgery-related complications and oncological outcome were determined. RESULTS: Toxicity was manageable, with 19/22 patients completing the planned chemotherapy protocol. The median time from initial diagnosis to surgery was 65.5 days. The median time from the end of chemotherapy to surgery was 22 days. After neoadjuvant treatment, tumour reduction of 69.5% was observed by CT scan and a 59.9% decrease of SUVmax (standard uptake value) was achieved on positron emission tomography/CT. No progressive disease was reported during preoperative chemotherapy and surgery was performed in all 22 patients. Four patients developed postoperative complications. After a median postoperative follow-up of 14.4 months, the actuarial overall and disease-free survival rates were 100 and 90%. CONCLUSION: Neoadjuvant chemotherapy followed by surgery and chemotherapy for LACC is safe without apparent increase of early and medium-term complications.
AIM: Preoperative chemotherapy followed by radical surgery is an attractive treatment for locally advanced colon cancer (LACC) given the promising results of this approach in other locally advanced tumours. The study evaluates the outcome and treatment-related complications of perioperative oxaliplatin- and capecitabine-based chemotherapy and surgery for clinical Stage III colon cancer. METHOD: Twenty-two consecutive patients with a CT-staged LACC were included. All were staged at baseline and before surgery. Surgery-related complications and oncological outcome were determined. RESULTS:Toxicity was manageable, with 19/22 patients completing the planned chemotherapy protocol. The median time from initial diagnosis to surgery was 65.5 days. The median time from the end of chemotherapy to surgery was 22 days. After neoadjuvant treatment, tumour reduction of 69.5% was observed by CT scan and a 59.9% decrease of SUVmax (standard uptake value) was achieved on positron emission tomography/CT. No progressive disease was reported during preoperative chemotherapy and surgery was performed in all 22 patients. Four patients developed postoperative complications. After a median postoperative follow-up of 14.4 months, the actuarial overall and disease-free survival rates were 100 and 90%. CONCLUSION: Neoadjuvant chemotherapy followed by surgery and chemotherapy for LACC is safe without apparent increase of early and medium-term complications.
Authors: A Venara; C Ridereau-Zins; L Toque; E Cesbron; S Michalak; E Lermite; C Aube; A Hamy Journal: Int J Colorectal Dis Date: 2015-02-27 Impact factor: 2.571
Authors: Jorge Arredondo; Patricia Martínez; Jorge Baixauli; Carlos Pastor; Javier Rodríguez; Fernando Pardo; Fernando Rotellar; Ana Chopitea; José Luís Hernández-Lizoáin Journal: J Gastrointest Oncol Date: 2014-04
Authors: Chris Hunter; Helena Blake; Nelesh Jeyadevan; Muti Abulafi; Ian Swift; Paul Toomey; Gina Brown Journal: Br J Radiol Date: 2016-05-26 Impact factor: 3.039
Authors: J Arredondo; E Pastor; V Simó; M Beltrán; C Castañón; M C Magdaleno; I Matanza; M Notarnicola; B Ielpo Journal: Tech Coloproctol Date: 2020-07-14 Impact factor: 3.781
Authors: Bodil Elisabeth Engelmann; Annika Loft; Andreas Kjær; Hans Jørgen Nielsen; Anne Kiil Berthelsen; Tina Binderup; Kim Brinch; Nils Brünner; Thomas Alexander Gerds; Gunilla Høyer-Hansen; Michael Holmsgaard Kristensen; Engin Yeter Kurt; Jan Erik Latocha; Gunnar Lindblom; Carsten Sloth; Liselotte Højgaard Journal: Scand J Gastroenterol Date: 2013-11-29 Impact factor: 2.423